FDA Approves Immune-Oncology Combination for Melanoma
the ONA take:
The US Food and Drug Administration (FDA) has granted accelerated approval to a regimen consisting of nivolumab and ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Nivolumab should be administered at a dose of 1 mg/kg intravenously over 60 minutes, followed by ipilimumab 3 mg/kg intravenously on the same day, every 3 weeks for four doses, then nivolumab 3 mg/kg over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
In regard to safety, the most common adverse reactions in patients receiving the combination in clinical trials were rash, pruritus, headache, vomiting, and colitis.
The most frequent grade 3 or 4 laboratory abnormalities were increased ALT, increased AST, increased lipase, increased amylase, hyponatremia, and lymphopenia.
Health care professionals should monitor for changes in liver function, renal function, and thyroid function.
The regimen was evaluated in 142 patients with unresectable or metastatic melanoma. Participants were randomly assigned to receive nivolumab plus ipilimumab or ipilimumab alone.
Results showed that the combination stopped cancer progression in 60% of patients with BRAF V600 wild-type disease compared with 11% in the ipilimumab alone arm.
Both drugs are also approved as monotherapy for the treatment of unresectable or metastatic melanoma.
Accelerated approval for nivolumab and ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|